Association between CCR5 Promoter Polymorphisms and Hepatitis B Virus Infection |
Hye-Young Chang3,4, Sang Hoon Ahn1,3, Do Young Kim1, Jeon-Soo Shin2, Yong-Soo Kim1,3,
Sun Pyo Hong5, Hyun Jae Chung5 , Soo-Ok Kim5, Wang Don Yoo5 , and Kwang-Hyub Han1,3,4 |
Dept. of Internal Medicine1, Dept. of Microbiology2, Institute of Gastroenterology3, Brain Korea 21 Project for Medical Science4, Yonsei University College of Medicine, GeneMatrix Inc.5 Seoul, Korea |
|
|
ABSTRACT |
|
Background/Aims Immunogenetic factors may play a role in determining the susceptibility of an individual
to viral infection. CCR5 promoter polymorphisms are known to be associated with HIV infection. However,
there has been no report on the association between CCR5 promoter polymorphism and HBV infection.
Therefore, we investigated the relationship between the CCR5 promoter polymorphism and HBV infection.
Methods A total of 377 patients were classified into two groups according to their HBV infection status: ①
the spontaneous clearance group (SC); HBsAg (-), anti-HBc (+), anti-HBs (+) ② the chronic HBsAg (+)
carrier group (CC); HBsAg (+), anti-HBc (+), anti-HBs (-). CCR5 polymorphisms were detected by
employing matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)-
based SNP scoring assay, termed Restriction Fragment Mass Polymorphism (RFMP), which exploits the
differences in molecular masses between the common allele and rare allele bases of interest. Results: We found
that the genotype frequencies of CCR5 A59029G significantly differed between the SC group (n=138) and CC
group (n=239) (P<0.05). The CCR5 59029A allelic genotype was associated with an increased risks of chronic
infection rather than spontaneous clearance (P=0.002), and the presence of the CCR5 59029G allele was
significantly associated with the spontaneous clearance of HBV (P=0.001). Strong linkage disequilibrium
between the CCR5-59029 and the CCR5-59353 polymorphic variants was identified. None of the 377 subjects
had the CCR5-32 bp deletion mutation. Conclusions: The CCR5 promoter polymorphisms at position 59029
might play a role in the clearance of HBV infection. This primary experimental evidence needs further studies
to clarify the clinical usefulness of CCR5 promoter polymorphisms as a target for the screening or treatment
of HBV infection. (Korean J Hepatol 2005;11:116-124) |
KeyWords:
Chemokine receptor 5, Hepatitis B virus, Genetic polymorphism |
|
|